The HLA-DR2 haplotype is associated with an increased proliferative response to the immunodominant CD4+T-cell epitope in human interferon-β

被引:24
作者
Stickler, M
Valdes, AM
Gebel, W
Razo, OJ
Faravashi, N
Chin, R
Rochanayon, N
Harding, FA
机构
[1] Univ Campus Biomed, Dept Med & Endocrinol, Rome, Italy
[2] Genencor Int, Palo Alto, CA 94304 USA
关键词
interferon-beta; multiple sclerosis; CD4+T-cell activation;
D O I
10.1038/sj.gene.6364027
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Human CD4+ T-cell epitopes were identified in interferon-beta (IFN-beta)-1b. A prominent peptide epitope region was found that induced a proliferative response in 16% of all donors tested. Responses corresponded to the presence of the HLA-DR2 haplotype. Responsive donors expressing the HLA-DQ6 allele showed an increased level of proliferation to the epitope as compared to peptide-responsive HLA-DQ6 negative donors. A similar result was found for HLA-DR15-expressing donors. PBMC from donors expressing HLA-DR15 were more likely to proliferate in response to IFN-beta in a whole-protein in vitro assay than donors who did not carry this haplotype. It is striking that the common DQ6 allele HLA-DQB1*0602 is found in linkage disequilibrium with HLA-DRB1*1501, and this combination defines the HLA genotype associated with the development of multiple sclerosis. The HLA association between a response to IFN-beta and MS might explain the prevalence of neutralizing antibody development, and may underlie the etiology of the disease.
引用
收藏
页码:1 / 7
页数:7
相关论文
共 27 条
  • [1] Barcellos LF, 2002, BRAIN, V125, P150
  • [2] HLA-DR2 dose effect on susceptibility to multiple sclerosis and influence on disease course
    Barcellos, LF
    Oksenberg, JR
    Begovich, AB
    Martin, ER
    Schmidt, S
    Vittinghoff, E
    Goodin, DS
    Pelletier, D
    Lincoln, RR
    Bucher, P
    Swerdlin, A
    Perick-Vance, MA
    Haines, JL
    Hauser, SL
    [J]. AMERICAN JOURNAL OF HUMAN GENETICS, 2003, 72 (03) : 710 - 716
  • [3] Persistent neutralizing antibodies abolish the interferon β bioavailability in MS patients
    Bertolotto, A
    Gilli, F
    Sala, A
    Capobianco, M
    Malucchi, S
    Milano, E
    Melis, F
    Marnetto, F
    Lindberg, RLP
    Bottero, R
    Di Sapio, A
    Giordana, MT
    [J]. NEUROLOGY, 2003, 60 (04) : 634 - 639
  • [4] MECHANISM AND REGULATION OF IMMUNOGLOBULIN ISOTYPE SWITCHING
    COFFMAN, RL
    LEBMAN, DA
    ROTHMAN, P
    [J]. ADVANCES IN IMMUNOLOGY, VOL 54, 1993, 54 : 229 - 270
  • [5] Bioavailability of interferon beta 1b in MS patients with and without neutralizing antibodies
    Deisenhammer, F
    Reindl, M
    Harvey, J
    Gasse, T
    Dilitz, E
    Berger, T
    [J]. NEUROLOGY, 1999, 52 (06) : 1239 - 1243
  • [6] Immunoglobulin subclasses in patients with neutralizing and nonneutralizing antibodies against TFN-β1b
    Deisenhammer, F
    Reindl, M
    Berger, T
    [J]. JOURNAL OF INTERFERON AND CYTOKINE RESEARCH, 2001, 21 (03) : 167 - 171
  • [7] Francis G, 2001, NEUROLOGY, V56, P1628
  • [8] Giordano Mara, 2002, Am J Pharmacogenomics, V2, P37, DOI 10.2165/00129785-200202010-00004
  • [9] HISTOCOMPATIBILITY ANTIGENS IN FAMILIAL MULTIPLE-SCLEROSIS IN A HIGH-RISK AREA OF THE DISEASE
    KINNUNEN, E
    KOSKIMIES, S
    LAGERSTEDT, A
    WIKSTROM, J
    [J]. JOURNAL OF THE NEUROLOGICAL SCIENCES, 1984, 65 (02) : 147 - 155
  • [10] Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis
    Leppert, D
    Lindberg, RLP
    Kappos, L
    Leib, SL
    [J]. BRAIN RESEARCH REVIEWS, 2001, 36 (2-3) : 249 - 257